Due to health issues, this site is no longer maintained and will be shut down shortly. |
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its product pipeline is PCS499, which is use for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on October 2, 2017 and is headquartered in Hanover, MD.
$0.46 -0.03 (-5.18%)
As of 03/24/2023 16:00:00 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.